Pfiz­er, Mer­ck KGaA say their PD-L1 Baven­cio al­so flunked PhI­II in the all-im­por­tant lung can­cer field

Play­ing catch-up in the crowd­ed PD-1/L1 field in can­cer R&D is prov­ing par­tic­u­lar­ly tough for Mer­ck KGaA and Pfiz­er $PFE.

The part­ners re­port­ed this morn­ing that their Phase III lung can­cer study JAVELIN Lung 200 failed the pri­ma­ry end­point for over­all sur­vival com­par­ing Baven­cio (the PD-L1 avelum­ab) against do­c­etax­el in sec­ond-line lung can­cer, a ma­jor field for all the play­ers in this par­tic­u­lar field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER